Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;17(2):122-9.
doi: 10.3779/j.issn.1009-3419.2014.02.10.

[Standard outcome measures for thymic malignancies]

[Article in Chinese]
James Huang  1 , Frank C Detterbeck  2 , Zuoheng Wang  2 , Patrick J Loehrer  3
Affiliations
Review

[Standard outcome measures for thymic malignancies]

[Article in Chinese]
James Huang et al. Zhongguo Fei Ai Za Zhi. 2014 Feb.
No abstract available

PubMed Disclaimer

Figures

注：本图已获得版权所有者© 2011 by the International Association for the Study of Lung Cancer复制许可。
1
胸腺瘤患者术后所有死因（A）和分期相关死因（B）。结果来自1980年至2009年样本量大于等于100例的研究结果的平均值。 Overall cause (A) and stage-specific (B) cause of death after resection of patients with thymoma. Results are an average of studies from 1980 to 2009 of100 patients reporting this data3.
注：本图已获得版权所有者© 2011 by the International Association for the Study of Lung Cancer复制许可。
2
Ⅲ期胸腺瘤术后患者的10年特异性生存，从总生存、死因、复发和第二原发肿瘤发生的相关数据评估[3]。 Specific outcomes for a stage Ⅲ resected thymoma at 10 years, estimated from data regarding overall survival, cause of death, incidence of recurrence, and incidence of other cancers[3].
注：本图已获得版权所有者© 2011 by the International Association for the Study of Lung Cancer复制许可。
3
队列样本量不同，持续10年的研究（A）和持续5年的研究（B）在精确估算生存上存在差异。竖线代表根据标准的指数生存模型（研究过程中患者是固定的并且零失访）估计出5年和10年生存的95%置信区间。 Variance in actuarial survival estimates by size of cohort for (A) a 10-year study duration and (B) a 5-year study duration. The vertical bars are 95% confidence intervals for the survival estimate at 5 and 10 years, based on a standard model of exponentially decreasing survival, a constant rate of accrual of patients during the course of the study until study termination, and no loss to follow-up. MST, median survival time.
See this image and copyright information in PMC

References

    1. de Jong W K, Blaauwgeers JLG, Schaapveld M, et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic proce-dures and therapy. Eur J Cancer. 2008;44:123–130. doi: 10.1016/j.ejca.2007.11.004. - DOI - PubMed
    1. Engel P, Marx A, Muller-Hermelink HK. Thymic tumours in Denmark. A retrospective study of 213 cases from 1970-1993. Pathol Res Pract. 1999;195:565–570. doi: 10.1016/S0344-0338(99)80006-5. - DOI - PubMed

    1. Detterbeck F, Parsons AM. Thymic tumors: a review of current diagnosis, classification, and treatment. In, Patterson GA, Cooper JD, Deslauriers J, Lerut A, Luketich JD, Rice TW, Pearson FG (eds). Thoracic and Esopha-geal Surgery, 3rd Ed. Philadelphia: Elsevier, 2008, Pp. 1589-1614.

    1. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymo-mas with special reference to their clinical stages. Cancer. 1981;48:2485–2492. doi: 10.1002/(ISSN)1097-0142. - DOI - PubMed
    1. Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44:359–367. - PubMed